Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial
<h3>Background</h3> We assessed the efficacy and safety of avelumab, an anti-programmed death ligand 1 (PD-L1) antibody, in patients with previously treated metastatic adrenocortical carcinoma (mACC). <h3>Methods</h3> In this phase 1b expansion cohort, patients with mACC and...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | inglés |
| Publicado: |
2018
|
| Acceso en línea: | https://doi.org/10.1186/s40425-018-0424-9 https://jitc.bmj.com/content/jitc/6/1/111.full.pdf |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|